Board of Directors

Bowdish V3 B&W 052-28971_5x5.jpg

Dr. Kathy Bowdish

President & CEO

Dr. Bowdish joined PIC Therapeutics as its President & CEO in August 2020, bringing more than 20 years of biopharmaceutical business and scientific leadership to the company. 


Kathy was most recently at Sanofi, where she launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early stage pioneering science for patients benefit, and more recently served as Vice President and Head of R&D Strategy.


Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies.  Kathy’s positions include President & CSO, Permeon Biologics; President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion. 


Kathy has served on the Boards of Directors of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most recently as an Observer on the DiCE Molecules Board. Kathy received her Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons, and her B.Sc. degree in biology from the College of William and Mary.

Gerry Brunk, MBA

Director

Gerry Brunk is a co-founder and Managing Director at Lumira Ventures, a healthcare venture capital firm. He has led investments in multiple biotechnology and medical device companies including enGene, Pharmasset, Engage Therapeutics, MAKO Surgical, KAI Pharmaceuticals, HistoSonics, Endotronix, Satsuma Pharmaceuticals and Cyrano Therapeutics. Prior to beginning his investing career in 2002, Gerry was a founder of several venture-funded healthcare companies, served as an engagement manager in the healthcare practice of Boston Consulting Group, and was a member of the investment banking group of Credit Suisse First Boston. He holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia where he studied biology and economics.

Gerry Brunk - Lumira Ventures_edited.jpg
belinda_edited_edited.jpg

Belinda Termeer

Director

Ms. Termeer leads the Termeer family office and holds a variety of directorship and governance roles at several of the Boston area's leading academic, charitable, and medical institutions. She is a member of the Board of Fellows and the Discovery Committee at Harvard Medical School and of the President's Council at Massachusetts General Hospital. In 2011, together with her late husband, Henri Termeer, she established the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital with the goal of developing a best in class center for personalized medicine, building on Mr. Termeer's work as Genzyme's CEO focused on rare diseases. In addition, Ms. Termeer is a member of the Women in Science and Engineering Committee at the Museum of Science and is a Trustee Emerita of the Boston Ballet.

Gerhard Wagner, PhD

Scientific Co-Founder, Director

Dr. Wagner is the Scientific Co-Founder of PIC Therapeutics and is world-renowned as a leading expert in NMR spectroscopy.  During his tenure at the University of Michigan in Ann Arbor, he developed triple-resonance methods and the procedures for studies of protein dynamics. Since 1990, Dr. Wagner has been a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.  His research focuses on eukaryotic translation initiation, transcriptional activation and membrane proteins in micelles and nanodiscs.  A particular focus of his research is on discovery and characterization of small molecule inhibitors of protein-protein interactions.  He has been elected to the German National Academy of Sciences (Leopoldina), The National Academy of Science USA and the American Academy of Arts and Sciences. Dr. Wagner obtained his PhD from the ETH Zürich in 1977 with NMR studies of protein dynamics.

GW_edited_edited.jpg

Alan E. Walts, PhD

Executive Chairman

Alan Walts, PhD, is a founding board member and currently serves as Executive Chairman of PIC Therapeutics. Alan also serves as Executive Chairman of Artax Biopharma, Chairman of Aura Biosciences, is a co-founder and Board Observer of Arrakis Therapeutics, a board observer at Amylyx Pharmaceuticals, and is a Director of the Termeer Foundation. Dr. Walts is a US-based Venture Partner with Advent Life Sciences and is an Advisory Board member of the ALS Investment Fund. He has over 25 years of industry experience at Genzyme in business development, business strategy, R&D, general management, and venture capital. Prior to leaving Genzyme in 2013, Dr. Walts most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures). He received a PhD in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.

AW_edited.jpg

Tal Zaks, M.D., Ph.D.

Director

Tal Zaks, M.D., Ph.D., is a Partner with OrbiMed. Dr. Zaks was recently the Chief Medical Officer at Moderna, where he led the development of the company’s COVID-19 vaccine and other key programs. Previously, Dr. Zaks held senior leadership positions in drug development at major pharmaceutical companies, including Sanofi and GlaxoSmithKline. Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University and conducted post-doctoral research at the U.S. National Institutes of Health.

Tal-Zaks_3663Bsq-Print_edited.jpg